From: Pathophysiological characterization of asthma transitions across adolescence
Remission % (n/N) | Persistent % (n/N) | Odds ratio | 95% Confidence interval | p-value | |
---|---|---|---|---|---|
Frequent wheeze (>4/year) | 38 (17/45) | 50 (54/108) | 0.6 | 0.3 – 1.2 | 0.17 |
Chest sounded wheezy with exercise | 57 (32/56) | 70 (87/125) | 0.6 | 0.3 – 1.1 | 0.10 |
Sleep affected by wheeze | 57 (28/49) | 48 (52/108) | 1.4 | 0.7 – 3.0 | 0.30 |
Sleep affected (≥1/week) | 4 (2/49) | 16 (17/108) | 0.2 | 0.1 – 0.9 | 0.04 |
Wheezing severe enough to limit speech | 13 (7/55) | 15 (18/122) | 0.8 | 0.3 – 2.1 | 0.72 |
Dry cough at night apart from a cold or chest infection | 54 (30/56) | 65 (80/124) | 0.6 | 0.3 – 1.2 | 0.16 |
On current asthma treatment | 76 (42/55) | 93 (114/123) | 0.2 | 0.1 – 0.6 | 0.002 |
On inhaled steroids at age 10 | 39.3 (22/56) | 30.7 (35/114) | 0.7 | 0.4 – 1.3 | 0.2 |
Atopy | 43 (20/47) | 70 (73/104) | 0.4 | 0.2 – 0.8 | 0.01 |
Wheeze | 89 (50/56) | 88 (110/125) | 1.1 | 0.4 – 3.1 | 0.80 |
Rhinitis | 46 (25/55) | 53 (64/121) | 0.7 | 0.4 – 1.4 | 0.36 |